Birchview Capital’s Cytokinetics CYTK Stock Holding History

Birchview Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Hold	30,000	–	–	1.2%	20
2026 Q1	$1.98M	Hold	30,000	–	–	1.13%	27
2025 Q4	$1.91M	Hold	30,000	–	–	1.12%	25
2025 Q3	$1.65M	Buy	30,000 +20,000	+200%	+$824K	1.24%	23
2025 Q2	$330K	Hold	10,000	–	–	0.33%	50
2025 Q1	$402K	Hold	10,000	–	–	0.35%	37
2024 Q4	$470K	Hold	10,000	–	–	0.38%	35
2024 Q3	$528K	Hold	10,000	–	–	0.46%	29
2024 Q2	$542K	Hold	10,000	–	–	0.5%	30
2024 Q1	$701K	Sell	10,000 -15,000	-60%	-$1.16M	0.57%	30
2023 Q4	$2.09M	Hold	25,000	–	–	1.63%	12
2023 Q3	$737K	Hold	25,000	–	–	0.63%	27
2023 Q2	$816K	Hold	25,000	–	–	0.61%	29
2023 Q1	$880K	Hold	25,000	–	–	0.69%	22
2022 Q4	$1.15M	Hold	25,000	–	–	0.81%	19
2022 Q3	$1.21M	Hold	25,000	–	–	0.85%	23
2022 Q2	$982K	Hold	25,000	–	–	0.71%	22
2022 Q1	$920K	Hold	25,000	–	–	0.66%	28
2021 Q4	$1.14M	Hold	25,000	–	–	0.74%	27
2021 Q3	$894K	Buy	25,000 +15,000	+150%	+$442K	0.61%	30
2021 Q2	$198K	Buy	+10,000	New	+$235K	0.12%	59
2019 Q4	–	Sell	-10,000	Closed	-$114K	–	53
2019 Q3	$114K	Hold	10,000	–	–	0.08%	43
2019 Q2	$113K	Hold	10,000	–	–	0.07%	49
2019 Q1	$81K	Hold	10,000	–	–	0.05%	51
2018 Q4	$63K	Hold	10,000	–	–	0.06%	50
2018 Q3	$99K	Hold	10,000	–	–	0.06%	51
2018 Q2	$83K	Hold	10,000	–	–	0.06%	52
2018 Q1	$72K	Hold	10,000	–	–	0.05%	48
2017 Q4	$82K	Hold	10,000	–	–	0.05%	40
2017 Q3	$145K	Buy	+10,000	New	+$137K	0.07%	37

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Birchview Capital's CYTK Position: Q2 2026 in Review

Birchview Capital held its Cytokinetics (CYTK) position steady in Q2 2026 at 30,000 shares worth $2.56M. The position accounts for 1.2% of the portfolio, ranked #20.

Birchview Capital first reported a position in CYTK in Q3 2017 and has held it in 30 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Birchview Capital held 30,000 shares of Cytokinetics worth $2.56M as of Q2 2026.
Birchview Capital left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up 1.2% of Birchview Capital's portfolio in Q2 2026, its #20 holding.
Birchview Capital first reported a position in Cytokinetics in Q3 2017 and has held it in 30 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.